(CIDRAP News) – New European studies reported today in Eurosurveillance suggest that this year's influenza vaccine is providing good protection against influenza B viruses but only moderate protection against type A—findings more or less consistent with earlier results in the United States.
(CIDRAP News) A recent case-control study estimates that the adjuvanted pandemic H1N1 influenza vaccine used in Canada was effective 93% of the time, a substantially higher figure than seen in several other studies and one that has raised some eyebrows among other flu vaccine researchers.
(CIDRAP News) Because of reports of increased fever and seizures in Australian and New Zealand children, the US government's Advisory Committee on Immunization Practices (ACIP) recommended today that a seasonal influenza vaccine made by CSL Ltd. should generally not be used in children from 6 months through 8 years old this fall and winter.
(CIDRAP News) The World Health Organization (WHO) said today that the fast-tracking of vaccines for pandemic H1N1 influenza won't compromise safety, while acknowledging that clinical data will be limited when the first doses are administered.
(CIDRAP News) Antiviral medications and vaccines are two tools that many government and health officials hope will stall the spread of an influenza pandemic, but each strategy has daunting challenges, according to a new report from Congress's Government Accountability Office (GAO).
(CIDRAP News) CSL Biotherapies, the US branch of an Australian vaccine producer, announced this week it has applied for Food and Drug Administration (FDA) approval to market a seasonal influenza vaccine in the United States.